Veea signs term sheet to merge with NovaGen, targets Nasdaq-listed health platform
VEEA•Next steps and closing conditions
Closing remains subject to definitive documentation and satisfaction of customary closing conditions.
Term sheet for merger with NovaGen
Veea entered a term sheet to combine with NovaGen, targeting a definitive business combination agreement within weeks.
The transaction aims to create a Nasdaq-listed longevity and precision-health platform alongside Veea’s ongoing edge AI infrastructure business.
Cornerstone investment and valuation
GeoNova Capital committed $10 million as a cornerstone investment in the combined company under a separate term sheet.
Management estimates the combined company’s value at about $750 million, based on internal projections and an independent valuation.
